IRIDEX Corp
NASDAQ:IRIX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
IRIDEX Corp
NASDAQ:IRIX
|
22.7m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
187.8B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
170.2B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
129B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
112.1B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
101.7B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.9B EUR |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
49.1B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.5B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.5B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
33.9B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
IRIDEX Corp
Glance View
IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company is headquartered in Mountain View, California and currently employs 119 full-time employees. The Company’s laser consoles products consist of Glaucoma, which includes Cyclo G6 laser and delivery devices used for the treatment of glaucoma; Medical Retina product, which includes IQ 532 Laser and IQ 577 Laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases, and its PASCAL Synthesis Photocoagulator for the treatment of retinal diseases; Surgical Retina, which includes OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems. Its laser probes products consist of Glaucoma, which include MicroPulse P3 Probe, G-Probe and G-Probe Illuminate, and Surgical Retina probes, which include EndoProbe family of products used in vitrectomy procedures.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for IRIDEX Corp is 38.2%, which is below its 3-year median of 41.1%.
Over the last 3 years, IRIDEX Corp’s Gross Margin has decreased from 43.3% to 38.2%. During this period, it reached a low of 38.2% on Sep 27, 2025 and a high of 44.5% on Dec 31, 2022.
